Improving adenoviral vectors and strategies for prostate cancer gene therapy

Imagem de Miniatura
Arquivos
art_TAMURA_Improving_adenoviral_vectors_and_strategies_for_prostate_cancer_2018.PDF (373.3 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2018
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
Citação
CLINICS, v.73, suppl.1, article ID UNSP e476s, 7p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Gene therapy has been evaluated for the treatment of prostate cancer and includes the application of adenoviral vectors encoding a suicide gene or oncolytic adenoviruses that may be armed with a functional transgene. In parallel, versions of adenoviral vector expressing the p53 gene (Ad-p53) have been tested as treatments for head and neck squamous cell carcinoma and non-small cell lung cancer. Although Ad-p53 gene therapy has yielded some interesting results when applied to prostate cancer, it has not been widely explored, perhaps due to current limitations of the approach. To achieve better functionality, improvements in the gene transfer system and the therapeutic regimen may be required. We have developed adenoviral vectors whose transgene expression is controlled by a p53-responsive promoter, which creates a positive feedback mechanism when used to drive the expression of p53. Together with improvements that permit efficient transduction, this new approach was more effective than the use of traditional versions of Ad-p53 in killing prostate cancer cell lines and inhibiting tumor progression. Even so, gene therapy is not expected to replace traditional chemotherapy but should complement the standard of care. In fact, chemotherapy has been shown to assist in viral transduction and transgene expression. The cooperation between gene therapy and chemotherapy is expected to effectively kill tumor cells while permitting the use of reduced chemotherapy drug concentrations and, thus, lowering side effects. Therefore, the combination of gene therapy and chemotherapy may prove essential for the success of both approaches.
Palavras-chave
Prostate Cancer, Adenovirus, p53, Chemotherapy, Gene Therapy
URI
https://observatorio.fm.usp.br/handle/OPI/29637
Referências
  1. Agell L, 2008, MODERN PATHOL, V21, P1470, DOI 10.1038/modpathol.2008.145
  2. [Anonymous], 2003, BIODRUGS, V17, P216
  3. Armstrong Cameron M, 2015, Am J Clin Exp Urol, V3, P64
  4. Asgari K, 1997, INT J CANCER, V71, P377, DOI 10.1002/(SICI)1097-0215(19970502)71:3<377::AID-IJC13>3.0.CO;2-D
  5. Atencio IA, 2006, CANCER GENE THER, V13, P169, DOI 10.1038/sj.cgt.7700870
  6. Azab BM, 2014, J CELL PHYSIOL, V229, P34, DOI 10.1002/jcp.24408
  7. Azarenko O, 2014, MOL CANCER THER, V13, P2092, DOI 10.1158/1535-7163.MCT-14-0265
  8. Bajgelman MC, 2008, VIROLOGY, V371, P8, DOI 10.1016/j.virol.2007.11.015
  9. Bettendorf O, 2008, GENE CHROMOSOME CANC, V47, P565, DOI 10.1002/gcc.20560
  10. Brooks JD, 1996, CANCER RES, V56, P3814
  11. Buller RE, 2002, CANCER GENE THER, V9, P553, DOI 10.1038/sj.cgt.7700472
  12. Buller RE, 2002, CANCER GENE THER, V9, P567, DOI 10.1037/sj.cgt.7700473
  13. Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
  14. Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02
  15. Chappell WH, 2012, CELL CYCLE, V11, P4579, DOI 10.4161/cc.22852
  16. Cheng WS, 2006, CANCER GENE THER, V13, P13, DOI 10.1038/sj.cgt.7700881
  17. Cmielova J, 2015, FOLIA BIOL-PRAGUE, V61, P60
  18. Dagher R, 2004, CLIN CANCER RES, V10, P8147, DOI 10.1158/1078-0432.CCR-04-1402
  19. Das K, 2005, CLIN GENET, V68, P40, DOI 10.1111/j.1399-0004.2005.00452.x
  20. de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
  21. Dean JL, 2013, CURR DRUG TARGETS, V14, P460
  22. Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178
  23. Debruyne Frans, 2002, Semin Urol Oncol, V20, P4, DOI 10.1053/suro.2002.35051
  24. DeWeese TL, 2001, CANCER RES, V61, P7464
  25. Don M, 2008, J INT MED RES, V36, P1273
  26. EASTHAM JA, 1995, CANCER RES, V55, P5151
  27. Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
  28. Freytag SO, 2002, CANCER RES, V62, P4968
  29. Freytag SO, 2003, CANCER RES, V63, P7497
  30. Freytag SO, 2007, MOL THER, V15, P1016, DOI 10.1038/mt.sj.6300120
  31. Freytag SO, 2007, MOL THER, V15, P636, DOI 10.1038/sj.mt.6300068
  32. Fujiwara T, 2006, J CLIN ONCOL, V24, P1689, DOI 10.1200/JCO.2005.03.4116
  33. Galletti E, 2007, CHEMMEDCHEM, V2, P920, DOI 10.1002/cmdc.200600308
  34. Galletti G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6548
  35. Ganansia-Leymarie Valerie, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P291, DOI 10.2174/1568011033482422
  36. Gjerset R, 2001, METH MOL B, V175, P495
  37. Guan YS, 2009, J ZHEJIANG UNIV-SC B, V10, P331, DOI 10.1631/jzus.B0820248
  38. Hazlehurst LA, 1999, CANCER RES, V59, P1021
  39. Heidenreich A, 2014, NAT REV UROL, V11, P189, DOI 10.1038/nrurol.2014.36
  40. Herman JR, 1999, HUM GENE THER, V10, P1239, DOI 10.1089/10430349950018229
  41. Horio Y, 2000, CANCER GENE THER, V7, P537, DOI 10.1038/sj.cgt.7700148
  42. Hwang C, 2012, THER ADV MED ONCOL, V4, P329, DOI 10.1177/1758834012449685
  43. Inoue A, 2000, CANCER LETT, V157, P105, DOI 10.1016/S0304-3835(00)00480-8
  44. KAPUSCINSKI J, 1986, P NATL ACAD SCI USA, V83, P6302, DOI 10.1073/pnas.83.17.6302
  45. KAPUSCINSKI J, 1985, BIOCHEM PHARMACOL, V34, P4203, DOI 10.1016/0006-2952(85)90275-8
  46. KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059
  47. Kluth M, 2014, INT J CANCER, V135, P1369, DOI 10.1002/ijc.28784
  48. Ko SC, 1996, HUM GENE THER, V7, P1683, DOI 10.1089/hum.1996.7.14-1683
  49. Kosaka T, 2011, J UROLOGY, V185, P2376, DOI 10.1016/j.juro.2011.02.016
  50. Kraaij R, 2007, PROSTATE, V67, P829, DOI 10.1002/pros.20560
  51. Kuball J, 2002, J CLIN ONCOL, V20, P957, DOI 10.1200/JCO.20.4.957
  52. Kumon H, 2015, CTS-CLIN TRANSL SCI, V8, P837, DOI 10.1111/cts.12362
  53. Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222
  54. Latham JPF, 2000, CANCER RES, V60, P334
  55. Lee SJ, 2002, MOL THER, V6, P415, DOI 10.1006/mthe.2002.0682
  56. Leroy B, 2013, NUCLEIC ACIDS RES, V41, pD962, DOI 10.1093/nar/gks1033
  57. Li X, 2008, CLIN CANCER RES, V14, P291, DOI 10.1158/1078-0432.CCR-07-0867
  58. Li Y, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-16
  59. Li YM, 2002, J UROLOGY, V167, P339, DOI 10.1016/S0022-5347(05)65465-1
  60. Li ZL, 2016, ACTA PHARMACOL SIN, V37, P1121, DOI 10.1038/aps.2016.59
  61. Liu CF, 2013, PROSTATE, V73, P418, DOI 10.1002/pros.22583
  62. Lu YS, 2013, ABSTR APPL ANAL, DOI 10.1155/2013/247307
  63. Lubaroff DM, 2014, IMMUNOL RES, V59, P229, DOI 10.1007/s12026-014-8531-2
  64. Lubaroff DM, 2009, CLIN CANCER RES, V15, P7375, DOI 10.1158/1078-0432.CCR-09-1910
  65. Miettinen S, 2009, ANTI-CANCER DRUG, V20, P589, DOI 10.1097/CAD.0b013e32832dad3d
  66. Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
  67. Nasu Y, 2007, MOL THER, V15, P834, DOI 10.1038/mt.sj.6300096
  68. Nguyen TV, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2015.21
  69. Ning X, 2011, CANCER GENE THER, V18, P444, DOI 10.1038/cgt.2011.15
  70. Nishizaki M, 2001, CLIN CANCER RES, V7, P2887
  71. Paller CJ, 2011, DRUG DES DEV THER, V5, P117, DOI 10.2147/DDDT.S13029
  72. Peng ZH, 2005, HUM GENE THER, V16, P1016, DOI 10.1089/hum.2005.16.1016
  73. Pisters LL, 2004, CLIN CANCER RES, V10, P2587, DOI 10.1158/1078-0432.CCR-03-0388
  74. Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770
  75. Radhakrishnan S, 2010, HUM GENE THER, V21, P1311, DOI 10.1089/hum.2010.019
  76. Rojas-Martinez A, 2013, CANCER GENE THER, V20, P642, DOI 10.1038/cgt.2013.56
  77. Rong BX, 2016, SCI REP-UK, V6, DOI 10.1038/srep39355
  78. Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985
  79. Ryan CJ, 2006, UROL ONCOL-SEMIN ORI, V24, P396, DOI 10.1016/j.urolonc.2005.09.003
  80. Schuler M, 1998, HUM GENE THER, V9, P2075, DOI 10.1089/hum.1998.9.14-2075
  81. Schuler M, 2001, J CLIN ONCOL, V19, P1750, DOI 10.1200/JCO.2001.19.6.1750
  82. Seth P, 1997, CANCER GENE THER, V4, P383
  83. Shen YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147173
  84. Shi CX, 2002, HUM GENE THER, V13, P211, DOI 10.1089/10430340252769743
  85. Shirakawa T, 2007, HUM GENE THER, V18, P1225, DOI 10.1089/hum.2007.074
  86. Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
  87. Singh J, 2010, CLIN INTERV AGING, V5, P187
  88. Small EJ, 2006, MOL THER, V14, P107, DOI 10.1016/j.ymthe.2006.02.011
  89. Sonpavde G, 2011, CLIN CANCER RES, V17, P7174, DOI 10.1158/1078-0432.CCR-11-1899
  90. Strauss BE, 2005, CANCER GENE THER, V12, P935, DOI 10.1038/sj.cgt.7700846
  91. Strauss BE, 2004, VIROLOGY, V321, P165, DOI 10.1016/j.virol.2003.12.021
  92. Tamura RE, 2017, HUM GENE THER, V28, P639, DOI 10.1089/hum.2016.139
  93. Tamura RE, 2016, CANCER BIOL THER, V17, P1221, DOI 10.1080/15384047.2016.1235655
  94. Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
  95. Teply BA, 2016, INDIAN J UROL, V32, P262, DOI 10.4103/0970-1591.191239
  96. Vrignaud P, 2014, DRUG DES DEV THER, V8, P1851, DOI 10.2147/DDDT.S64940
  97. Wang GX, 2012, J INT MED RES, V40, P317, DOI 10.1177/147323001204000132
  98. WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045
  99. WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079
  100. Wonganan P, 2009, CANCER GENE THER, V16, P405, DOI 10.1038/cgt.2008.99
  101. Wu L, 2001, GENE THER, V8, P1416, DOI 10.1038/sj.gt.3301549
  102. Xiao JE, 2017, ONCOL LETT, V13, P3676, DOI 10.3892/ol.2017.5901
  103. Xiong L, 2007, CLIN CANCER RES, V13, P5463
  104. Yamanaka K, 2005, MOL CANCER THER, V4, P187
  105. YANG CL, 1995, CANCER RES, V55, P4210
  106. Yang YF, 2014, GENE THER, V21, P723, DOI 10.1038/gt.2014.46
  107. Yoo GH, 2010, AM J OTOLARYNG, V31, P78, DOI 10.1016/j.amjoto.2008.10.002
  108. Yoo GH, 2004, LARYNGOSCOPE, V114, P1871, DOI 10.1097/01.mlg.0000147914.51239.ed
  109. Yu DC, 2001, CANCER RES, V61, P517
  110. Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947
  111. ZHANG WW, 1994, CANCER GENE THER, V1, P5

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03